Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNLX NASDAQ:NKTX NASDAQ:RADX NASDAQ:SEER On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNLXGenelux$3.40+11.1%$2.82$1.60▼$5.89$115.55M-0.34173,416 shs193,889 shsNKTXNkarta$2.00+9.3%$1.81$1.31▼$7.55$129.85M0.71.02 million shs1.53 million shsRADXRadiopharm Theranostics$4.27-4.0%$4.55$3.50▼$50.82$35.08MN/A18,236 shs28,891 shsSEERSeer$2.12$2.09$1.59▼$2.63$124.80M1.57266,509 shs44,319 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNLXGenelux-0.65%-11.56%-5.26%+16.35%+16.79%NKTXNkarta+0.55%+1.10%-3.17%+1.10%-77.13%RADXRadiopharm Theranostics+5.45%+6.71%-13.09%+3.49%+444,999,900.00%SEERSeer+0.95%-2.30%+4.95%+7.89%+9.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNLXGenelux1.2131 of 5 stars3.60.00.00.02.60.00.0NKTXNkarta1.9377 of 5 stars3.60.00.00.02.71.70.6RADXRadiopharm TheranosticsN/AN/AN/AN/AN/AN/AN/AN/ASEERSeer2.2171 of 5 stars3.02.00.00.01.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNLXGenelux 3.20Buy$17.75422.06% UpsideNKTXNkarta 3.13Buy$14.33616.67% UpsideRADXRadiopharm Theranostics 3.50Strong Buy$12.00181.03% UpsideSEERSeer 2.00Hold$3.0041.51% UpsideCurrent Analyst Ratings BreakdownLatest RADX, GNLX, SEER, and NKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025NKTXNkartaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.005/15/2025NKTXNkartaWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform5/15/2025NKTXNkartaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/12/2025RADXRadiopharm TheranosticsThinkEquitySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025GNLXGeneluxBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSpeculative Buy ➝ Speculative Buy$25.00 ➝ $23.005/1/2025RADXRadiopharm TheranosticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNLXGeneluxN/AN/AN/AN/A$0.76 per shareN/ANKTXNkartaN/AN/AN/AN/A$5.78 per shareN/ARADXRadiopharm Theranostics$1.68M20.00N/AN/AN/A∞SEERSeer$15.06M8.29N/AN/A$5.54 per share0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNLXGenelux-$29.87M-$0.88N/AN/AN/AN/A-93.04%-74.17%8/13/2025 (Estimated)NKTXNkarta-$108.79M-$1.51N/AN/AN/AN/A-26.64%-21.62%8/12/2025 (Estimated)RADXRadiopharm TheranosticsN/AN/A0.00∞N/AN/AN/AN/AN/ASEERSeer-$86.60M-$1.41N/AN/AN/A-560.90%-24.69%-22.13%8/6/2025 (Estimated)Latest RADX, GNLX, SEER, and NKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SEERSeer-$0.39N/AN/AN/AN/AN/A8/13/2025N/AGNLXGenelux-$0.22N/AN/AN/AN/AN/A8/12/2025Q2 2025NKTXNkarta-$0.37N/AN/AN/AN/AN/A5/14/2025Q1 2025NKTXNkarta-$0.44-$0.43+$0.01-$0.43N/AN/A5/13/2025Q1 2025SEERSeer-$0.37-$0.34+$0.03-$0.34$3.25 million$4.21 million5/8/2025Q1 2025GNLXGenelux-$0.24-$0.21+$0.03-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNLXGeneluxN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/ARADXRadiopharm TheranosticsN/AN/AN/AN/AN/ASEERSeerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNLXGeneluxN/A4.674.67NKTXNkartaN/A14.4814.48RADXRadiopharm TheranosticsN/AN/AN/ASEERSeerN/A19.3418.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNLXGenelux37.33%NKTXNkarta80.54%RADXRadiopharm TheranosticsN/ASEERSeer75.20%Insider OwnershipCompanyInsider OwnershipGNLXGenelux9.30%NKTXNkarta8.40%RADXRadiopharm TheranosticsN/ASEERSeer11.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNLXGenelux1037.76 million34.25 millionNot OptionableNKTXNkarta14070.96 million65.00 millionOptionableRADXRadiopharm TheranosticsN/A7.88 millionN/AN/ASEERSeer16058.87 million52.23 millionOptionableRADX, GNLX, SEER, and NKTX HeadlinesRecent News About These CompaniesHere's Why We're Watching Seer's (NASDAQ:SEER) Cash Burn Situation4 hours ago | finance.yahoo.comOperation Kalanemi: Fake Seer Exposed as Bangladeshi NationalJuly 16 at 7:18 AM | devdiscourse.comDGates fixed at Panchamasali Peetha at Kudala Sangama and locked, but seer has no idea who did itJuly 16 at 7:18 AM | thehindu.comPrime Video’s ‘Bloodaxe’ Adds Six To CastJuly 16 at 7:18 AM | msn.comIn African politics, the rampant belief in witchcraft fortifies some and vexes othersJuly 16 at 7:18 AM | msn.comOld video of Bright The Seer predicting death of former leader emergesJuly 14 at 12:04 PM | gistreel.comGBright the Seer shares what will happen to Bola Tinubu in 2027July 14 at 12:04 PM | msn.comBuhari’s death; Old video of seer predicting former head of state passing emergesJuly 14 at 7:04 AM | gistreel.comGOld video of Bright The Seer predicting death of former Nigerian leader emergesJuly 14 at 7:04 AM | gistreel.comGBuhari’s death: Old prophecy on former head of state’s demise trends, as Bright Seer shares videoJuly 13, 2025 | msn.comVoice of a nation, seer of the West IndiesJuly 13, 2025 | trinidadexpress.comTUttarakhand cracks down on bogus seers, 127 arrested during Kanwar Yatra sweepJuly 12, 2025 | indiatoday.inIHVAC Specialist Dale Admas of Triple A Home Services Shares Insights on SEER Rating and AC Efficiency in HelloNationJuly 12, 2025 | biznes.newseria.plBNo reservation demand until CM change: Panchamasali seerJuly 12, 2025 | uniindia.comUWill not demand 2A reservation as long as Siddaramaiah remains CM, says SeerJuly 12, 2025 | msn.comAl Seer Marine secures AED 760 million financeJuly 11, 2025 | shippingherald.comSAl Seer Marine obtains AED 760 million loan from ADCB for diversified fleet growthJuly 10, 2025 | en.portnews.ruEAl Seer seals $207m loan to drive tanker and gas carrier expansionJuly 10, 2025 | tradewindsnews.comTAbu Dhabi Al Seer Marine secures $207mln facility from ADCBJuly 9, 2025 | zawya.comZAl Seer Marine secures AED760 million financing facility from ADCBJuly 9, 2025 | msn.comSeer (NASDAQ:SEER) Trading 1.4% Higher - Here's What HappenedJuly 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRADX, GNLX, SEER, and NKTX Company DescriptionsGenelux NASDAQ:GNLX$3.40 +0.34 (+11.11%) Closing price 04:00 PM EasternExtended Trading$3.20 -0.20 (-5.74%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Nkarta NASDAQ:NKTX$2.00 +0.17 (+9.29%) Closing price 04:00 PM EasternExtended Trading$1.98 -0.01 (-0.75%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Radiopharm Theranostics NASDAQ:RADX$4.27 -0.18 (-4.04%) As of 03:59 PM EasternRadiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.Seer NASDAQ:SEER$2.13 +0.01 (+0.71%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
